JP2023543528A5 - - Google Patents
Info
- Publication number
- JP2023543528A5 JP2023543528A5 JP2023542834A JP2023542834A JP2023543528A5 JP 2023543528 A5 JP2023543528 A5 JP 2023543528A5 JP 2023542834 A JP2023542834 A JP 2023542834A JP 2023542834 A JP2023542834 A JP 2023542834A JP 2023543528 A5 JP2023543528 A5 JP 2023543528A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- substituted
- compound according
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082324P | 2020-09-23 | 2020-09-23 | |
| US63/082,324 | 2020-09-23 | ||
| US202063092970P | 2020-10-16 | 2020-10-16 | |
| US63/092,970 | 2020-10-16 | ||
| PCT/US2021/051504 WO2022066734A1 (en) | 2020-09-23 | 2021-09-22 | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023543528A JP2023543528A (ja) | 2023-10-16 |
| JP2023543528A5 true JP2023543528A5 (enExample) | 2024-10-02 |
| JP7797513B2 JP7797513B2 (ja) | 2026-01-13 |
Family
ID=78135207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542834A Active JP7797513B2 (ja) | 2020-09-23 | 2021-09-22 | がんの処置に有用なピロロ［３，２－ｃ］ピリジン－４－オン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230364070A1 (enExample) |
| EP (1) | EP4217070A1 (enExample) |
| JP (1) | JP7797513B2 (enExample) |
| KR (1) | KR20230094197A (enExample) |
| AU (1) | AU2021347288A1 (enExample) |
| CA (1) | CA3196712A1 (enExample) |
| CL (1) | CL2023000856A1 (enExample) |
| IL (1) | IL301532A (enExample) |
| MX (1) | MX2023003362A (enExample) |
| TW (1) | TW202229272A (enExample) |
| WO (1) | WO2022066734A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| EP4217352A4 (en) | 2020-09-23 | 2024-04-10 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2023173083A1 (en) * | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| CA3246654A1 (en) | 2022-03-24 | 2023-09-28 | Antares Therapeutics, Inc. | METHODS FOR SYNTHESIZING EGFR INHIBITORS |
| US20250282795A1 (en) * | 2022-04-20 | 2025-09-11 | Celyn Therapeutics, Inc. | EGFR Inhibitors in cancer treatment |
| CN121712773A (zh) * | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| WO2024254298A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| WO2025049904A1 (en) | 2023-08-31 | 2025-03-06 | Scorpion Therapeutics, Inc. | Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation |
| EP4534085A1 (en) | 2023-10-03 | 2025-04-09 | Scorpion Therapeutics, Inc. | Compounds for use in methods of treating cancer |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906194B2 (en) | 2003-10-08 | 2005-06-14 | Massachusetts Instititue Of Technology | Fluorescence assay for kinase activity |
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| WO2012087943A2 (en) | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
| ES2620316T3 (es) | 2012-05-11 | 2017-06-28 | Bayer Pharma Aktiengesellschaft | Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer |
| ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
| HK1218750A1 (zh) | 2013-03-21 | 2017-03-10 | Bayer Pharma Aktiengesellschaft | 3-杂芳基取代的吲唑 |
| WO2014147204A1 (en) | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| WO2014176475A2 (en) | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| US9765058B2 (en) | 2013-06-21 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| HK1223097A1 (zh) | 2013-06-21 | 2017-07-21 | Bayer Pharma Aktiengesellschaft | 杂芳基取代的吡唑 |
| ES2652305T3 (es) | 2013-06-21 | 2018-02-01 | Bayer Pharma Aktiengesellschaft | Pirazoles heteroaril sustituidos |
| HK1222846A1 (zh) | 2013-06-21 | 2017-07-14 | Bayer Pharma Aktiengesellschaft | 取代的苄基吡唑 |
| CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3157914B1 (en) | 2014-06-17 | 2018-09-26 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| TN2017000329A1 (en) | 2015-01-28 | 2019-01-16 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN107922389A (zh) | 2015-06-17 | 2018-04-17 | 拜耳制药股份公司 | 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮 |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| JP6141568B1 (ja) | 2015-09-01 | 2017-06-07 | 大鵬薬品工業株式会社 | 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩 |
| US20200216439A1 (en) | 2015-12-16 | 2020-07-09 | Bayer Pharma Aktiengesellschaft | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones |
| KR102771603B1 (ko) | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| CN111032655B (zh) | 2017-08-31 | 2022-09-02 | 达纳-法伯癌症研究所股份有限公司 | Egfr和/或her2抑制剂和使用方法 |
| EP3700904B1 (en) | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| WO2019165385A1 (en) | 2018-02-23 | 2019-08-29 | Fulton Group N.A., Inc. | Inward-firing premix fuel combustion burner |
| EP3755323A4 (en) | 2018-02-23 | 2021-11-24 | The Regents Of The University Of Michigan | EGFR DIMER DISRUPTORS AND THEIR USES |
| CN112236417A (zh) | 2018-06-14 | 2021-01-15 | 达纳-法伯癌症研究所股份有限公司 | 作为her2抑制剂的氰基喹啉酰胺化合物及使用方法 |
| WO2019246541A1 (en) | 2018-06-21 | 2019-12-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| DK3959211T3 (da) * | 2019-04-24 | 2026-04-27 | Bayer Ag | 4h-pyrrol[3,2-c]pyridin-4-on-forbindelser |
| US12403135B2 (en) * | 2019-04-24 | 2025-09-02 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| US20240307362A1 (en) * | 2019-04-24 | 2024-09-19 | Bayer Aktiengesellschaft | 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS |
-
2021
- 2021-09-22 KR KR1020237013431A patent/KR20230094197A/ko active Pending
- 2021-09-22 AU AU2021347288A patent/AU2021347288A1/en active Pending
- 2021-09-22 EP EP21791189.0A patent/EP4217070A1/en active Pending
- 2021-09-22 CA CA3196712A patent/CA3196712A1/en active Pending
- 2021-09-22 US US18/027,316 patent/US20230364070A1/en active Pending
- 2021-09-22 WO PCT/US2021/051504 patent/WO2022066734A1/en not_active Ceased
- 2021-09-22 JP JP2023542834A patent/JP7797513B2/ja active Active
- 2021-09-22 IL IL301532A patent/IL301532A/en unknown
- 2021-09-22 MX MX2023003362A patent/MX2023003362A/es unknown
- 2021-09-23 TW TW110135434A patent/TW202229272A/zh unknown
-
2023
- 2023-03-23 CL CL2023000856A patent/CL2023000856A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023543528A5 (enExample) | ||
| US11802127B2 (en) | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | |
| JP7187729B2 (ja) | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 | |
| US20230286981A1 (en) | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | |
| JP2023548657A5 (enExample) | ||
| US10189834B2 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| AU2022402390A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| JP2023513675A (ja) | Ｋｒａｓ変異に関連する癌の予防または治療のための医薬組成物 | |
| CN104945401B (zh) | Ip化合物及它们在治疗中的应用 | |
| JP2021523159A (ja) | Ｅｒｂｂ受容体阻害剤 | |
| JPWO2018143315A1 (ja) | キナゾリン化合物 | |
| JP2020504742A (ja) | 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体 | |
| TW201920150A (zh) | 作為jak激酶抑制劑之吡唑并及三唑并雙環化合物 | |
| JP2021176820A (ja) | キナゾリン化合物を有効成分とする医薬組成物 | |
| US20210347775A1 (en) | Deuterated Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | |
| US20230241073A1 (en) | Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with ron mutantation, and method using same | |
| US20230202992A1 (en) | Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same | |
| JP2021511382A (ja) | （３ｓ，４ｓ）−１−シクロプロピルメチル−４−｛［５−（２，４−ジフルオロ−フェニル）−イソオキサゾール−３−カルボニル］−アミノ｝−ピペリジン−３−カルボン酸 （１−ピリミジン−２−イル−シクロプロピル）−アミドの結晶形 | |
| CN117561255A (zh) | 作为mek抑制剂的3,4-二氢-2,7-萘啶-1,6(2h,7h)-二酮化合物 | |
| JP2024047569A (ja) | Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン | |
| EA040712B1 (ru) | Макроциклические соединения и их использование |